Biogen Inc
NASDAQ: BIIB
$159.99
-$4.90 (-3.0%)
Closing Price on November 15, 2024
BIIB Articles
Reuters: Cybercrime is spreading fast on Facebook. Reuters: GM will seek to sell most of its assets to a new company. Reuters: Madoff got 150 years in prison. Reuters: AIG (AIG)...
Published:
Last Updated:
Reuters: The Supreme Court delays Chrysler deal. Reuters: The cleared ten banks to repay TARP include JPMorgan (JPM), Goldmand Sachs (GS), American Express (AXP), Cpaital One(COF), State Street...
Published:
Last Updated:
Reuters: Rio Tinto (RTP) has killed a deal with Chinalco for one with BHP (BHP). Reuters: US regulators insisted JP Morgan (JPM) and Amex (AXP) raise money to exit the TARP. Reuters: ...
Published:
Last Updated:
This weekend will be a potentially important oncology and cancer news weekend for drug and biotech stocks. The American Association for Cancer Research Meeting will actually have a 100th annual...
Published:
Acorda Therapeutics, Inc. (NASDAQ: ACOR) is taking it right on the chin this morning. The company announced that it has received a “refuse to file letter” from the FDA regarding its New Drug...
Published:
Last Updated:
Billionaire and activist investor Carl Icahn has made some large changes to his portfolio holdings. He and Icahn Capital, L.P. have not been immune to the market sell-off as you have seen in his...
Published:
Biogen Idec (NASDAQ: BIIB) is coming under fire from activist investor Carl Icahn this morning. A release came out as a "shareholder proposal" from Icahn Partners LP. He is asking for four...
Published:
Last Updated:
Biogen Idec Inc. (NASDAQ: BIIB) is set to report earnings on Friday morning. What many investors probably want to know is if these results — or more importantly its guidance — show that this...
Published:
Last Updated:
These are some of the top pre-market downgrades and cautious calls we have seen from Wall Street analysts this Wednesday morning: Amylin Pharmaceuticals (AMLN) Cut to Sell at Canaccord Adams. Biogen...
Published:
Last Updated:
These are some of the top analyst upgrades and positive research calls we have seen from Wall Street analysts with more than two hours until the market opens this Tuesday morning: ARM Holdings (ARMH)...
Published:
Last Updated:
It is still fairly thin in analyst upgrades and downgrades as this week marks the return of investment banking and research departments from what is nearly a two-week hiatus. Here are the few...
Published:
Last Updated:
There may be some speculation that drug giant Pfizer Inc. (NYSE: PFE) is looking at expansion through acquisitions. The FT reported that the world’s largest pharmaceutical company is willing to...
Published:
Last Updated:
Biogen Idec Inc. (NASDAQ: BIIB) just came out with an SEC filing showing that on December 11, 2008, regulatory agencies were notified of a confirmed case of progressive multifocal...
Published:
Last Updated:
It seems that short sellers have no real direction in the major NASDAQ biotech stocks from mid-November to late-November. Generally you see a pattern. This month the only pattern seems to be one...
Published:
These are some of the top pre-market upgrades from analysts which we have seen in the early hours this Monday morning: Acorda Therapeutics (ACOR) Raised to Outperform at Baird. Biogen Idec (BIIB)...
Published: